REGENXBIO Inc.
About REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $170.4M
- Net income
- -$193.9M
- Total assets
- $453.0M
- Market cap
- $314.3M
- Operating margin
- -94.6%
- Net margin
- -113.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $170.4M
- Operating expenses
- $331.6M
- Operating income
- -$161.2M
- Income tax
- $0
- Net income
- -$193.9M
- EPS (basic)
- $-3.76
- EPS (diluted)
- $-3.76
Balance sheet
- Total assets
- $453.0M
- Current assets
- $281.3M
- Total liabilities
- $350.3M
- Current liabilities
- $118.1M
- Shareholders’ equity
- $102.7M
Cash flow
- Operating cash flow
- -$124.0M
- Investing cash flow
- -$15.9M
- Financing cash flow
- $116.8M
- Net cash flow
- -$23.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $314.3M
- EPS (diluted)
- $-3.76
- Shares outstanding
- 51.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 17, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $193.9M in FY2025.
- Revenue declined 64% from FY2021 to FY2025.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review REGENXBIO Inc..
Write a review
News about REGENXBIO Inc.
News & sentiment via Polygon.io
